Attorneys at Sidley Austin LLP examine the issue of drug price reporting rules under Medicaid and enforcement risks under the ...

BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical ...

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional ...

Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for its rare disease drug after the Food and Drug Administration declined to approve the treatment under a new ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

State lawmakers are looking to fix the fallout of a billing mistake by the Virginia Department of Health (VDH) that triggered ...

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCES ...

BOSTON, MA / ACCESS Newswire / February 17, 2026 / Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with app ...

Many TNBC tumors exhibit elevated intracellular iron levels and heightened oxidative stress, creating a biological reliance on redox-active metals to sustain proliferation and epigenetic modifications ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD ...

The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program ...

NSA Labs conducts high-quality neurohistology studies on accelerated timelines. Its proprietary MultiBrain® and MultiCord® ...